Evidence Report/Technology Assessment Number 103

Pharmacological and Surgical Treatment of Obesity

File Inventory


Prepared by:

Southern California-RAND Evidenced-Based Practice Center
Santa Monica, CA

Investigators
Director
   Paul G. Shekelle, M.D., Ph.D.
Senior Statistician/Co-Director
   Sally C. Morton, Ph.D.
Project Manager/Policy Analyst
   Margaret Maglione, M.P.P.
Statisticians
   Marika Suttorp, M.S.
   Wenli Tu, M.S.
Reviewers
   Zhaoping Li, M.D., Ph.D.
   Melinda Maggard, M.D.
   Walter A. Mojica, M.D., M.P.H.
   Lisa Shugarman, Ph.D.
   Vanessa Solomon, M.A.
   Programmer/Analyst
   Lara Jungvig, B.A.
Medical Editor
   Sydne J. Newberry, Ph.D.
Staff Assistants
   Donna Mead, B.A.
   Shannon Rhodes, M.F.A.

File Name Description Software and Version Size
01front.doc Title page, Preface, Structured Abstract, Table of Contents Word® 2002 55KB, 8 pages
02chap1.doc Chapter 1. Introduction: Prescription Weight Loss Medications, Bariatric Surgical Procedures Word® 2002 107KB, 6 pages
03chap2.doc Chapter 2. Methods: Original Proposed Key Questions; Technical Expert Panel; Literature Search; Article Review; Meta-Analyses of Weight Loss Medications; Medication Adverse-Events Meta-Analysis; Surgery Analyses Word® 2002 142KB, 12 pages
04chap3.doc Chapter 3. Results: Results of the Literature Search; Efficacy of Medications; Efficacy of Surgery for Weight Loss; Use of Obesity Medication and Bariatric Surgery in the Adolescent and Pediatric Population Word® 2002 273KB, 18 pages
05chap4.doc Chapter 4. Discussion: Limitations, Conclusions, Future Research Word® 2002 39KB, 5 pages
06refs.doc Reference List Word® 2002 166KB, 14 pages
07tbl1.doc Table 1. Adverse events in medication studies Word® 2002 202KB, 2 pages
08tbl2.doc Table 2. Adverse events in surgery studies Word® 2002 115KB, 5 pages
09tbl3.doc Table 3. Surgical procedure categories Word® 2002 38KB, 1 page
10tbl4&5.doc Table 4. Meta-analysis of weight loss in placebo-controlled trials of orlistat at 6 months; Table 5. Meta-analysis of weight loss in placebo-controlled trials of Orlistat at 12 months Word® 2002 126KB, 1 page
11tbl6.doc Table 6. Meta-analysis of adverse events in RCTs of orlistat Word® 2002 113KB, 1 page
12tbl7&8.doc Table 7. Meta-analysis of weight loss in placebo-controlled trials of fluoxetine at 6 months; Table 8. Meta-analysis of weight loss in placebo-controlled trials of fluoxetine at 12 months Word® 2002 46KB, 1 page
13tbl9.doc Table 9. Meta-analysis of adverse events in RCTs of fluoxetine for obesity Word® 2002 118KB, 1 page
14t10&11.doc Table 10. Meta-analysis of weight loss in placebo controlled trials of bupropion at 6-12 months; Table 11. Meta-analysis of adverse events in RCTs of bupropion Word® 2002 113KB, 1 page
15t12&13.doc Table 12. Meta-analysis of weight loss in placebo controlled trials of topiramate at 6 months; Table 13. Meta-analysis of adverse events in RCTs of topiramate Word® 2002 128KB, 1 page
16tbl14.doc Table 14. Summary of findings regarding medications for weight loss Word® 2002 32KB, 1 page
17tbl15.doc Table 15. Summary of results of Cochrane review of surgery for morbid obesity Word® 2002 29KB, 1 page
18tbl16.doc Table 16. Weight loss following bariatric surgery by procedure (at 12 months followup), pooled results by study type Word® 2002 44KB, 1 page
19tbl17.doc Table 17. Weight loss following bariatric surgery by procedure (at ? 36 months followup), pooled results by study type Word® 2002 43KB, 1 page
20tbl18.doc Table 18. Mortality analysis, surgical procedures Word® 2002 29KB, 1 page
21tbl19.doc Table 19. Postoperative adverse events by bariatric procedure (RYGB versus VBG, Band, or BPD), results pooled by study type Word® 2002 174KB, 5 pages
22tbl20.doc Table 20. Postoperative adverse events following bariatric procedures differs by operative approach (open versus laparoscopic), pooled results by study type Word® 2002 108KB, 3 pages
23fig1.doc Figure 1a. Literature flow; Figure 1b. Literature flow, continued Word® 2002 87KB, 2 pages
24fig2.doc Figure 2. Pooled analysis: 8- to 12-week trials of sibutramine, 10-15 mg daily Word® 2002 46KB, 1 page
25fig3.doc Figure 3. Pooled analysis: 16- to 24-week trials of sibutramine, 10-15 mg daily Word® 2002 62KB, 1 page
26fig4.doc Figure 4. Pooled analysis: 44- to 54-week trials of sibutramine, 10-15 mg daily Word® 2002 44KB, 1 page
27fig5.doc Figure 5. Pooled analysis: orlistat, 6 months Word® 2002 48KB, 1 page
28fig6.doc Figure 6. Pooled analysis: orlistat, 12 months Word® 2002 58KB, 1 page
29fig7&8.doc Figure 7. Pooled analysis: fluoxetine, 6 months; Figure 8. Pooled analysis: fluoxetine, 12 months Word® 2002 77KB, 1 page
30fig9.doc Figure 9. Pooled analysis: bupropion, 6-12 months Word® 2002 42KB, 1 page
31fig10.doc Figure 10. Pooled analysis: topiramate Word® 2002 44KB, 1 page
32appa.doc Appendix A. Preliminary Search Methodologies—Obesity; Obesity Updates to Aberdeen Searches Methodologies Word® 2002 54KB, 9 pages
33appb.doc Appendix B: Figure 1. Screening form for literature; Figure 2. QRF Word® 2002 142KB, 7 pages
34apcet1.doc Appendix C: Evidence Table-Medication Word® 2002 547KB, 24 pages
35apcet2.doc Appendix C: Evidence Table-Surgery Word® 2002 729KB, 40 pages
36appd.doc Appendix D: Table 1. Technical Expert Panel members; Table 2. Peer Reviewers Word® 2002 39KB, 1 page
37appe.doc Appendix E: Obesity Peer and TEP Review Word® 2002 243KB, 35 pages
38appf.doc Appendix F: Included Studies Word® 2002 153KB, 13 pages
39appg.doc Appendix G: Excluded Studies Word® 2002 348KB, 44 pages

AHRQ Publication No. 04-E028-2
Current as of July 2004


Internet Citation:

Pharmacological and Surgical Treatment of Obesity. File Inventory, Evidence Report/Technology Assessment Number 103. AHRQ Publication No. 04-E028-2, July 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/obesphinv.htm


Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services